Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Institution	Shares	Value	Change
Tcg Crossover Management	6,007,834	$801M	DECREASED
Darwin Global Management, Ltd	3,621,583	$348M	INCREASED
Helikon Investments	2,787,131	$371M	INCREASED
Vestal Point Capital	2,349,443	$313M	INCREASED
Jupiter Topco	1,913,933	$255M	NEW

Abivax SA American Depositary Shares (ABVX) Ownership & Trading Activity

Top Institutional Holders